Home

JOHN MENDLEIN

CIK 1238362 · CEO and Director · last filed 2025-05-30

JOHN MENDLEIN is a CEO and Director who has filed 41 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for FATE, was dated Dec 29, 2025. Across all open-market trades the lifetime net is +$42.5K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $2.3M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.26M

Companies

5

Total Filings

41

Lifetime Open-Market Net

$42.5K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
FATE Director 311,231 $2.80 $871.4K -$338.1K 16 2025-05-30
Omega Therapeutics, Inc. (OMGA) Delisted Director — $0.14 — $0 3 2024-06-21
LIFE CEO and Director 43,956 $31.61 $1.39M $380.6K 16 2019-05-10
EDIT Director — $2.88 — $0 2 2017-06-19
Monogram Biosciences, Inc. (MGRM) Delisted Director — $6.00 — $0 3 2009-01-21

Recent Filings

41 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-12-29 FATE Notice (144) −38,428 -$38.9K EDGAR
2025-05-30 FATE Grant (A) — $0 EDGAR
2024-06-21 Omega Therapeutics, Inc. (OMGA) Delisted Grant (A) — $0 EDGAR
2024-06-11 FATE Grant (A) — $0 EDGAR
2023-06-09 Omega Therapeutics, Inc. (OMGA) Delisted Grant (A) — $0 EDGAR
2023-06-07 FATE Grant (A) — $0 EDGAR
2023-01-20 FATE Exer (M) +28,461 $39.0K EDGAR
2023-01-13 FATE Buy (P) +124,679 $698.1K EDGAR
2022-06-13 FATE Grant (A) +8,650 $0 EDGAR
2022-06-10 Omega Therapeutics, Inc. (OMGA) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 41
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.